MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study - Wikidata - wikimedia - TriplyDB

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

http://www.wikidata.org/entity/Q28285807

about

Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions Immunotherapy for cervical cancer: Research status and clinical potential The influence of delivery vectors on HIV vaccine efficacy A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Therapeutic Vaccine Strategies against Human Papillomavirus.Immunology and Immunotherapy of Head and Neck Cancer Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.Progress and challenges in the vaccine-based treatment of head and neck cancers.Therapeutic vaccines against human papillomavirus and cervical cancer.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Immunologic treatments for precancerous lesions and uterine cervical cancer.Current state in the development of candidate therapeutic HPV vaccines Human papillomavirus related oropharyngeal cancer.Therapeutic human papillomavirus vaccines: current clinical trials and future directions Emerging human papillomavirus vaccines

P2860

Q26777442-D4A55D39-5626-4BB7-8049-300479C8581B Q34033763-9EB0EC7F-3828-46F4-8C68-240D277F257B Q34077543-FF6FD94B-79D0-4614-A15F-60C3ED50637F Q34121681-8F62B521-ED42-4548-90B3-EBE5829E5D1C Q34729962-DE01F29D-412D-4E4C-828C-CDD51CF14AAA Q35053133-5D01D32D-A85E-4C5C-9ACD-974F3830B370 Q35571248-F48D2797-0215-4EBF-A011-F5017732A140 Q35826752-2D7C5216-2D61-495F-BFC2-D68B20491845 Q36100837-695C08F2-26C4-4450-885C-85B7F16206E4 Q36849770-207158B5-B7B5-467C-8EDD-292B58284733 Q36987072-1225A608-734E-4B41-BBF7-92DE1E6A4475 Q37224926-24807AEC-EED8-4E4A-8E0A-25D572F2235F Q37418916-461887BE-2986-4685-BF9A-C302105438EF Q37579334-719F7D8A-A0D3-4EDC-9402-895220C5387D Q37703113-4585C392-0B73-4793-A2C8-F6BBEF14EF9C Q38743922-D2D220DA-AEDE-4CBD-B2B8-3BAD0CFDAB9E Q40152615-92AD08C2-3F19-4A25-BF35-81CB28CF8280 Q56937332-0B743361-8710-45E8-A697-EFED8380B6BE Q56967486-0172D3EA-4BA9-4070-9473-D0672D68FCFB

P2860

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

http://www.wikidata.org/entity/Q28285807

description

2007 nî lūn-bûn

@nan

2007 թուականին հրատարակուած գիտական յօդուած

@hyw

2007 թվականին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@ast

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@en

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@nl

type

label

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@ast

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@en

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@nl

prefLabel

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@ast

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@en

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@nl

P1433

Q28285807-4D006712-C3E1-41F4-BB72-D449E21C9D8C

P1476

Q28285807-3EDB6BA6-365D-4920-ABFD-08781D2F9C75

P2093

Q28285807-22F9DFEF-51E4-474B-9104-293772907ED2

Q28285807-2BCDF000-545D-4182-869B-B9EE5F25FE55

Q28285807-4F274B70-C1B1-4215-BD7F-D92F29ED9F31

Q28285807-59B5086E-603A-4C7D-934D-4FCDB8FF1BDB

Q28285807-808C945C-6F33-46DE-8DA2-CCF40624D937

Q28285807-95D68968-6EF9-4D75-8B3C-9C1168CD6405

Q28285807-A1E72557-7CB4-42F7-A937-F0861DAC07C3

Q28285807-AA74309D-8661-4BF8-A822-2EA6FD3F4880

Q28285807-B116E82D-2F4F-4D17-A699-D28FFE1B2DBC

Q28285807-B7C9950A-F5A6-4D7B-9F59-FF8C4E431C5D

P2860

Q28285807-256EC26F-B42E-4425-9E19-2D46FEF623AB

Q28285807-69A2AB5A-F0D6-43E1-A431-B7B684A85F05

Q28285807-BC53006B-ADE5-4D24-B9F0-156C4717FD12

P2888

Q28285807-4ECD990D-D098-4807-BAB1-83C5E0F4C8EC

P304

Q28285807-48FC1200-46AD-49BB-BD0D-8909C33191DF

P31

Q28285807-97835932-A536-45C3-81A4-1CC1F82C7DAC

P356

Q28285807-37187AA7-D5E8-4AED-ACAF-418C0241B086

P407

Q28285807-241A0D64-51F9-4AFF-90EB-61DF8813364D

P433

Q28285807-E9C0FFEC-CCD0-4AFD-A2AD-94FE4300D7E0

P478

Q28285807-66D78E9C-DA27-4782-A424-8D993F306C05

P577

Q28285807-6B7E4777-9A39-4AFB-9AFD-A49CAD467535

P6179

Q28285807-39F1D131-9709-4ABF-BB20-300E2EC7BD31

P698

Q28285807-5F44CCF2-6297-40EC-A11C-DE8194D95A15

P356

00063030-200721010-00006

P1433

P1476

MVA E2 recombinant vaccine in ...... condyloma: a phase I/II study

@en

P2093

Alejandro Andrade-Manzano

http://www.w3.org/2001/XMLSchema#string

Alfonso de la Garza

http://www.w3.org/2001/XMLSchema#string

Antonio Albarran Y Carvajal

http://www.w3.org/2001/XMLSchema#string

Axel Ramírez Varela

http://www.w3.org/2001/XMLSchema#string

Benitez Jose Cecilio Cruz Quiroz

http://www.w3.org/2001/XMLSchema#string

Eduardo Vazquez Zea

http://www.w3.org/2001/XMLSchema#string

Ernesto Mendez Fuentez

http://www.w3.org/2001/XMLSchema#string

Ismael Díaz Estrada

http://www.w3.org/2001/XMLSchema#string

Mario López Contreras

http://www.w3.org/2001/XMLSchema#string

Ricardo Rosales

http://www.w3.org/2001/XMLSchema#string

P2860

An overview of sexually transmitted diseases. Part II.

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.

Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention

P2888

00063030-200721010-00006

P304

47-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00063030-200721010-00006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026348032

http://www.w3.org/2001/XMLSchema#string

P698

17263589

http://www.w3.org/2001/XMLSchema#string